Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11845239 | 0.82 | KDM4E (0.51) | MAPTALDH1A1LMNATDP1KDM4E | |
| SCHEMBL6827151 | 0.74 | KDM4E (0.58) | MAPTALDH1A1LMNATDP1KDM4E | |
| SCHEMBL15364617 | 0.74 | ALDH1A1 (0.50) | MAPTALDH1A1LMNATDP1KDM4E | |
| SCHEMBL11189920 | 0.72 | MAPT (0.62) | MAPTALDH1A1LMNATDP1RAB9A | |
| SCHEMBL11492548 | 0.72 | PPARG (0.59) | ALDH1A1POLBALOX5PPARGPPARA | |
| SCHEMBL31153743 | 0.71 | MMP8 (0.41) | MAPTALDH1A1LMNATDP1SMN1; SMN2 | |
| SCHEMBL15615316 | 0.70 | KMT2A (0.48) | ALDH1A1RAB9ASMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL16047613 | 0.70 | ALDH1A1 (0.46) | MAPTALDH1A1LMNATDP1KDM4E | |
| SCHEMBL16047641 | 0.69 | ALDH1A1 (0.51) | MAPTALDH1A1LMNATDP1KDM4E | |
| SCHEMBL8550932 | 0.69 | CYP1A2 (0.46) | MAPTALDH1A1LMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399426-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | Active Pass Pharmaceuticals, Inc. (CA) | 2004-03-24 | — | — | EP | disclosed |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-10-09 | — | — | US | disclosed |
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2002100836-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
| US-3940394-A | ANTILIPEMIC | SANTILLI ARTHUR A | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | MAPT 35/4885ALDH1A1 1910/4885LMNA 621/4885 |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | MAPT 35/4885ALDH1A1 1910/4885LMNA 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.